Nidufexor (LMB-763) is a drug which acts as a partial agonist of the farnesoid X receptor (FXR).

It has reached Phase II clinical trials for the treatment of diabetic nephropathy and nonalcoholic steatohepatitis.

[1][2]

This pharmacology-related article is a stub.

You can help Wikipedia by expanding it.